BioSpace News Archive

Lisa Stockman Mauriello was diagnosed with ALS in January and is seeking access to Biogen’s tofersen (BIIB067) through the Right to Try Act. Her case has reinvigorated the ALS community and its fight for expanded access to investigational therapies for this cruel, always fatal disease.

Disappointing data from two Phase Ib/IIa trials for both lead Huntington’s disease antisense candidates have pushed Wave Life Sciences to shelve the assets and focus on its next generation of therapies.

AbbVie won the NDA on the strength of definitive results in a Phase III ADVANCE trial, where atogepant met all six secondary endpoints at the 30-60 mg dose range, proving statistically significant in heading off migraines in nearly 2500 adult participants who experience them between 4-14 days per month.

The first four patients that were administered BS01, Bionic Sight’s investigational gene therapy for advanced retinitis pigmentosa (RP), all reported the ability to detect light and motion. Two of the patients were also able to detect direction.

Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for March 30, 2021.

Exebacase Phase 3 DISRUPT study enrollment ongoing in patients with Staph aureus bloodstream infections; results from interim futility analysis anticipated in H2 2021

Vividion Therapeutics, Inc., a biotechnology company utilizing novel discovery technologies to unlock high value, traditionally undruggable targets with precision therapeutics for devastating cancers and immune disorders, today announced that Patricia “Patty” Allen, who has served as acting chief financial officer of Vividion since January 2021, has joined the company as full-time CFO and that Brian Koh, M.D., has been appointed as head of translational sciences

– New ADMIRAL study complements ongoing U.S. studies and marks first step in global expansion of clinical development of STK-001 – – Study will evaluate safety and PK of multiple doses of STK-001 starting at 30mg; Enrollment and dosing anticipated to begin in 2H 2021 – – STK-001 has the potential to be the first disease-modifying therapy to address the root cause of Dravet syndrome, a severe and progressive genetic epilepsy –

Horizon Therapeutics plc to Resupply Market With TEPEZZA ® (teprotumumab-trbw) for the Treatment of Thyroid Eye Disease (TED) Beginning in April

Merck Announces Acquisition of Alydia Health on behalf of its Planned Spinoff of Organon Acquisition underscores Organon’s commitment to improving the health of women by addressing unmet medical need in maternal health through safer childbirth